Tacoma BH Cushman Integrated Care Clinic

Located in Bethesda, MD, Tacoma BH Cushman Integrated Care Clinic operates within the MD regulatory framework as a licensed addiction-treatment provider. The facility offers a continuum of care across multiple levels — Outpatient, MAT, Dual Dx — which means it can, in principle, hold a patient across the arc of a typical treatment episode. Structural evaluation of this facility's clinical posture requires review of state licensing records, accreditation status, and payer-network contracts.

Care levels at Tacoma BH Cushman Integrated Care Clinic

Level-of-care documentation: The facility offers a continuum of care across multiple levels — Outpatient, MAT, Dual Dx — which means it can, in principle, hold a patient across the arc of a typical treatment episode. The practical question is whether it is genuinely strong at each level, or whether one level is the core business and the others are secondary. Under MHPAEA 2024 medical-necessity criteria disclosure, plan-specific criteria for each of these levels must be available to patients upon request. Mismatch between documented clinical need and offered level of care is a common source of authorization denial.

Insurance and payment

Payment and insurance posture: Tacoma BH Cushman Integrated Care Clinic operates primarily on commercial insurance. The implication for patients: higher typical cost-share, potentially more intensive programming, and the full burden of MHPAEA parity-rule dynamics — including appeal rights when the plan denies. Pre-admission Verification of Benefits (VOB) documentation should include: specific plan product and network status, deductible status at time of admission, coinsurance rate applicable, prior authorization status and turnaround, and out-of-pocket accumulation. Under MHPAEA 2024 disclosure rules, plan-specific medical-necessity criteria must be available on request.

Before you call

Pre-admission due-diligence for Tacoma BH Cushman Integrated Care Clinic: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via MD behavioral-health regulator inspection records. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.